Richmond Pharmacology ishonoured to be attending the 2024 Annual Meeting of the Japanese Society ofClinical Pharmacology and Therapeutics (JSCPT). This event in Omiya bringstogether leading clinical pharmacologists to discuss the latest advancements indrug development and therapeutic innovation. The conference will featurevarious
scientific sessions, posterpresentations, and networking opportunities.
To connect with our teamduring the event, please reach out to arrange a meeting.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
